Csl Limited (ASX:CSL)


right-arrow Created with Sketch. -3.32 (-1.21%)
MCAP $131.0B
Last trade 16.10pm 19/01/2022 20mins delayed

Latest Announcements

17/01/2022CSLCsl Limited
07/01/2022CSLCsl Limited
29/12/2021CSLCsl Limited
22/12/2021CSLCsl Limited
21/12/2021CSLCsl Limited
20/12/2021CSLCsl Limited
16/12/2021 Price SensitivePSCSLCsl Limited

Company Overview

CSL Limited is an Australia-based biotechnology company. The Company is engaged in developing and delivering biotherapies and influenza vaccines that treat people with serious diseases and chronic medical conditions. It offers treatments for people who are living with conditions in immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. The Company operates through two segments: CSL Behring and Seqirus. CSL Behring manufactures, markets, and develops plasma therapies (plasma products and recombinants), conducts early-stage research on plasma and non-plasma therapies, excluding influenza, receives license and royalty income from the commercialization of intellectual property and undertakes the administrative and corporate function required to support the Company. Seqirus segment manufactures and distributes non-plasma biotherapeutic products and develops influenza related products. Its products include PRIVIGEN, IDELVION and AFSTYLA.

CSL in the news

CSL (CSL) completes its $6.3 billion institutional placement to fund its acquisition…
Australian drug manufacturing giant CSL (CSL) has ended FY21 with a US$2.37…
Biotech giant CSL (CSL) has closed its global commercialisation and licence agreement…

Search Previous Announcements